全文获取类型
收费全文 | 578篇 |
免费 | 12篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 14篇 |
妇产科学 | 2篇 |
基础医学 | 10篇 |
临床医学 | 14篇 |
内科学 | 16篇 |
皮肤病学 | 1篇 |
神经病学 | 171篇 |
特种医学 | 43篇 |
外科学 | 67篇 |
综合类 | 23篇 |
预防医学 | 8篇 |
眼科学 | 6篇 |
药学 | 6篇 |
肿瘤学 | 216篇 |
出版年
2023年 | 5篇 |
2022年 | 6篇 |
2021年 | 13篇 |
2020年 | 13篇 |
2019年 | 10篇 |
2018年 | 9篇 |
2017年 | 12篇 |
2016年 | 11篇 |
2015年 | 20篇 |
2014年 | 35篇 |
2013年 | 28篇 |
2012年 | 39篇 |
2011年 | 42篇 |
2010年 | 31篇 |
2009年 | 61篇 |
2008年 | 34篇 |
2007年 | 30篇 |
2006年 | 33篇 |
2005年 | 26篇 |
2004年 | 14篇 |
2003年 | 21篇 |
2002年 | 20篇 |
2001年 | 13篇 |
2000年 | 14篇 |
1999年 | 16篇 |
1998年 | 9篇 |
1997年 | 9篇 |
1996年 | 13篇 |
1995年 | 3篇 |
1994年 | 3篇 |
1993年 | 2篇 |
1987年 | 1篇 |
1985年 | 1篇 |
排序方式: 共有597条查询结果,搜索用时 15 毫秒
1.
《Clinical lung cancer》2019,20(4):e452-e462
BackgroundThe purpose of the study was to evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) for centrally located, primary non–small-cell lung cancer (NSCLC).Materials and MethodsSystematic search of 4 databases (PubMed, MEDLINE, EMBASE, and Cochrane Library) was performed for literature published until May 9, 2018. Primary (overall survival [OS] and local control [LC] rates) and secondary (Grade ≥3 toxicity) endpoints were reported.ResultsThirteen studies encompassing 599 patients with central NSCLCs were included. Median values of T1 tumor proportion, tumor size, and median survival were 55.3% (range, 0%-75%), 3.3 (range, 2.1-4.1) cm, and 26 (range, 14-68.9) months, respectively. Pooled rates of 1-, 2-, and 3-year OS rates were 84.3% (95% confidence interval [CI], 75.7-90.3), 64.0% (95% CI, 52.9-72.2), and 50.5% (95% CI, 39.4-61.5), respectively. Pooled rates of 1-, 2-, and 3-year LC rates were 89.4% (95% CI, 80.8-94.4), 82.2% (95% CI, 71.7-89.4), and 72.2% (95% CI, 55.0-84.7), respectively. Pooled rate of Grade ≥3 complication was 12.0% (95% CI, 7.3-19.0). Meta-regression analyses showed significant positive relationships between biologically equivalent dose using an α/β of 10 Gy in the linear quadratic model (BED10Gy) and 1- and 2-year LC rates (P < .001 and P < .001), and 1- and 2-year OS rates (P = .0178 and P = .032), and Grade ≥3 complication rate (P = .0029). In subgroup comparisons between BED10Gy <100 Gy versus ≥100 Gy, 1- and 2-year LC rates were significantly different but not for OS and Grade ≥3 complication rates.ConclusionOur results suggests that SBRT is potent for tumor control in central NSCLC, although complications should be further minimized through optimization of dose-fractionation scheme and accurate planning. Using BED10Gy ≥100 Gy yielded higher LC rates, and dose escalation was related to OS, LC, and complications. 相似文献
2.
3.
4.
5.
6.
7.
《Cancer radiothérapie》2014,18(5-6):468-472
Over the last decade, there have been many technical advances in radiation therapy, such as the spread of intensity-modulated conformal radiotherapy, and the rise of stereotactic body radiation therapy. By allowing better dose-to-target conformation and thus better organs at risk-sparing, these techniques seem very promising, particularly in the field of head and neck tumors. The present work aims at analyzing the level of evidence and recommendation supporting the use of high-technology radiotherapy in head and neck neoplasms, by reviewing the available literature. 相似文献
8.
9.
《European annals of otorhinolaryngology, head and neck diseases》2014,131(4):223-226
Surgery has been long considered to be the treatment of choice for glomus jugulare paragangliomas, as it is the only modality able to totally eradicate the tumour. However, despite considerable progress in interventional radiology and nerve monitoring, surgery is associated with an unacceptably high complication rate for a benign tumour, explaining the growing place of radiotherapy in the management of these tumours. This review of the literature confirms the efficacy of conformal radiotherapy with or without intensity modulation and stereotactic radiotherapy, which both achieve tumour control rates ranging from 90% to almost 100% of cases, but for different tumour volumes, almost constant stabilization or even improvement of symptoms, and a considerably lower rate of adverse effects than with surgery. However, radiotherapy remains contraindicated in the presence of intracranial invasion or extensive osteomyelitis. In the light of these results, together with the improved quality of life and a better knowledge of the natural history of this disease, many authors propose radiotherapy as first-line treatment for all glomus jugulare paragangliomas regardless of their size, particularly in patients with no preoperative deficits. 相似文献
10.
目的 总结射波刀分次治疗听神经瘤的初步结果和设计治疗计划技巧.方法 应用射波刀分次治疗29例听神经瘤.肿瘤平均最大直径为31 mm.肿瘤平均体积为13.2 cm3 (0.3~36.0 cm3).设计治疗计划时,将射线束控制在150~ 200条之间,使治疗计划有良好的适形性,同时提高肿瘤内高剂量区范围.2例巨大肿瘤照射4次,3例小肿瘤照射2次,其余24例照射3次.平均随访时间21个月.结果 1例巨大肿瘤患者在治疗后10个月死亡,其余28例肿瘤中,6例缩小50%以上,15例缩小20%,7例肿瘤无变化.13例保持原有有效听力,1例听力明显下降,1例听力从无效改善为有效,其余患者为无效听力.无面瘫,3例患者出现脑积水,1例出现脑干水肿,治疗后水肿消失.结论 射波刀分次治疗听神经瘤的初步疗效满意,不良反应较轻;为高龄、不适合手术、部分肿瘤较大的听神经瘤患者提供又一治疗手段,但长期疗效和不良反应有待进一步随访. 相似文献